Finally, we examined the therapeutic effect of human IL-34 + IL-4 Mf in a liver fibrosis model using immunodeficient NSG mice in which human PBMCs had been administered (see the Methods section). This evidence concerns the gene IL34 and Hepatic fibrosis.